Publication: Incretins: The novel therapy of type 2 diabetes
Issued Date
2008-06-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-47149103357
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.91, No.6 (2008), 943-954
Suggested Citation
Nuntakon Thongtang, Apiradee Sriwijitkamol Incretins: The novel therapy of type 2 diabetes. Journal of the Medical Association of Thailand. Vol.91, No.6 (2008), 943-954. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19641
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Incretins: The novel therapy of type 2 diabetes
Author(s)
Other Contributor(s)
Abstract
Type 2 diabetes mellitus is a worldwide health problem. Adequate glycemic control can help to prevent many chronic diabetic complications. Despite the availability of several classes of oral hypoglycemic agents and insulin, many patients fail to achieve adequate glycemic control. Incretins are gut hormones produced in response to ingestion of nutrients. Glucagon-like peptide-1 (GLP-1), one of the incretin hormones, has pleiotropic actions on the control of blood glucose. Clinical trials with the incretin mimetic and Dipeptidyl peptidase-IV inhibitors demonstrate promising results in the improvement of glucose homeostasis.